PSI

Overview

PSI describes itself as a full-service global contract research organization (CRO). The company positions its work around on-time delivery of pivotal Phase 2 and Phase 3 clinical trials.

Therapeutic areas

• Oncology, including breast, lung, prostate, colorectal, and ovarian cancers
• Gastroenterology, including inflammatory bowel disease, Crohn's disease, and ulcerative colitis
• Hematology, including multiple myeloma, lymphomas, leukemias, and hemophilia
• Cell and gene therapy, including CAR-T, gene editing, stem cell therapy, and immunotherapy
• Neurology, including multiple sclerosis, stroke, Alzheimer's, and Parkinson's
• Infectious diseases, including UTI, pneumonia, skin infections, sepsis, and hepatitis
• Radiopharmaceuticals, across oncology and neurology
• Respiratory, including COPD, IPF, and asthma
• Other areas, including allergy, immunology, rheumatology, endocrine and metabolic diseases, cardiology, and nephrology and urology

Delivery approach

The website states that PSI meets enrollment milestones and budgets, and that about 90% of clients are repeat or referral customers. It also describes a team of experts across 58 countries and a feasibility platform for clinical trial planning. A separate agentic AI platform is presented for study milestone management.

Recognition and expansion

PSI says it is recognized by independent industry organizations and sponsor surveys. A newsroom headline references a new office in Osaka as part of continued Japan expansion.